Crispin-Ortuzar, Mireia http://orcid.org/0000-0002-4351-3709
Woitek, Ramona http://orcid.org/0000-0002-9146-9159
Reinius, Marika A. V. http://orcid.org/0000-0002-9778-3317
Moore, Elizabeth
Beer, Lucian http://orcid.org/0000-0003-4388-7580
Bura, Vlad
Rundo, Leonardo
McCague, Cathal http://orcid.org/0000-0002-9588-267X
Ursprung, Stephan http://orcid.org/0000-0003-2476-178X
Escudero Sanchez, Lorena http://orcid.org/0000-0003-3464-9206
Martin-Gonzalez, Paula
Mouliere, Florent http://orcid.org/0000-0001-7043-0514
Chandrananda, Dineika http://orcid.org/0000-0002-8834-9500
Morris, James
Goranova, Teodora
Piskorz, Anna M.
Singh, Naveena
Sahdev, Anju http://orcid.org/0000-0001-8520-3031
Pintican, Roxana
Zerunian, Marta
Rosenfeld, Nitzan http://orcid.org/0000-0002-2825-4788
Addley, Helen
Jimenez-Linan, Mercedes
Markowetz, Florian http://orcid.org/0000-0002-2784-5308
Sala, Evis
Brenton, James D. http://orcid.org/0000-0002-5738-6683
Article History
Received: 27 May 2022
Accepted: 20 September 2023
First Online: 24 October 2023
Competing interests
: F.Mo., D.C., A.P., J.D.B. and N.R. are inventors of the patent “Enhanced detection of target DNA by fragment size analysis” (WO/2020/094775). N.R. and J.D.B. are inventors of the patent “TAm-Seq v2 method for ctDNA estimation” (WO 2016/009224A1). T.G. is an employee of and owns shares from AstraZeneca. F.Ma. and J.D.B. are founders and directors of Tailor Bio Ltd and own shares in Tailor Bio Ltd. J.D.B. has received honoraria and personal payments from AstraZeneca, GSK and Clovis Oncology. M.C.O. has received honoraria from GSK. E.S. is co-founder and shareholder of Lucida Medical Ltd. L.R. has received consulting fees from Lucida Medical Ltd. The remaining authors declare no competing interests.